Capital Research Global Investors lifted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 18.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 494,472 shares of the medical research company’s stock after buying an additional 76,117 shares during the quarter. Capital Research Global Investors’ holdings in Bio-Rad Laboratories were worth $149,820,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. CWM LLC raised its holdings in Bio-Rad Laboratories by 26.7% during the 4th quarter. CWM LLC now owns 256 shares of the medical research company’s stock worth $78,000 after buying an additional 54 shares during the period. OneDigital Investment Advisors LLC boosted its holdings in shares of Bio-Rad Laboratories by 1.9% in the third quarter. OneDigital Investment Advisors LLC now owns 2,954 shares of the medical research company’s stock valued at $828,000 after buying an additional 55 shares during the period. RK Asset Management LLC increased its position in shares of Bio-Rad Laboratories by 0.5% during the fourth quarter. RK Asset Management LLC now owns 14,573 shares of the medical research company’s stock worth $4,415,000 after acquiring an additional 71 shares in the last quarter. Geneos Wealth Management Inc. increased its position in shares of Bio-Rad Laboratories by 115.2% during the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after acquiring an additional 76 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its holdings in shares of Bio-Rad Laboratories by 6.7% during the third quarter. Jones Financial Companies Lllp now owns 1,276 shares of the medical research company’s stock worth $346,000 after acquiring an additional 80 shares during the period. 65.24% of the stock is owned by institutional investors.
Bio-Rad Laboratories Price Performance
NYSE:BIO opened at $291.73 on Tuesday. The stock has a market capitalization of $7.81 billion, a PE ratio of 48.06 and a beta of 1.08. Bio-Rad Laboratories, Inc. has a 1-year low of $219.94 and a 1-year high of $343.12. The firm has a fifty day simple moving average of $282.42 and a 200 day simple moving average of $291.50. The company has a current ratio of 3.21, a quick ratio of 2.37 and a debt-to-equity ratio of 0.12.
Analysts Set New Price Targets
Several research firms recently commented on BIO. Weiss Ratings cut shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 6th. Royal Bank Of Canada initiated coverage on Bio-Rad Laboratories in a report on Friday, May 15th. They set an “outperform” rating and a $320.00 target price for the company. Wall Street Zen downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Citigroup lowered Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and cut their price target for the company from $375.00 to $300.00 in a report on Tuesday, April 7th. Finally, Wells Fargo & Company reduced their price objective on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating for the company in a research report on Friday, May 1st. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $303.33.
Check Out Our Latest Research Report on BIO
Bio-Rad Laboratories Profile
Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.
Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.
Featured Stories
- Five stocks we like better than Bio-Rad Laboratories
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
